Instytut Zywnosci i Zywienia w Warszawie, Warszawa
Bibliografia
1. Argen J.J., Valve R., Vidregen H., et al.: Postprandial lipemic response is modified by the polymorphism at codon 54 of the fatty acid binding protein 2 gene. Arterioscler. Thromb. Vase. Biol., 1998, 18, 1606.
2. Baier L.J., Sechettini J.C., Knowler W.C.: An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J. Clin. Invest. 1995, 95, 1281.
3. Boerwinkle E., Brown S., Shareft A.R., et al.: Apolipoprotein E polimorphism influences postprandial retinyl palmitate but not trigliceryde concentration. Am. J. Hum. Genet., 1994, 54, 341.
4. Cobb M.M., Teitlebaum H., Risch N.: Influence of dietary fat, apolipoprotein E phenotype and sex on plasma lipoprotein levels. Circulation 1992, 86, 849.
5. Cooper G.S., Umbach D.M.: Are vitamin D receptor polymorphism associated with bone mineral density? A meta-analysis. J. Bone Miner. Res., 1996, 11, 1841.
6. Cusi D., Barlassina C., Azzani T., et al.: Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997, 349, 1353.
7. Dowson- Hughes B., Harris S., Finneran S.: Calcium absorption on high and low calcium intakes in relation to vitamin D receptor gene. J. Clin. Endocrinol. Metab., 1995, 80, 3657.
8. Fisher R.M., Burke H., Nicaud V., et al.: Effect of variation in the apo AIV gene on body mass index, and fasting and postprandial lipids in the European Atherosclerosis Research Study II. J. Lipid Res., 1999, 40, 287.
9. Fujimoto K., Machidori H., Iwakiri, et al.: Effect of intravenous administration of apolipoprotein AIV on patterns of feeding, drinking and ambulatory activity in rats. Brain Res., 1993, 608, 233.
10. Gerhard G.T., Duell P.B.: Homocysteine and atherosclerosis. Curr. Opin. Lipidol., 1999, 10, 417.
11. Girard J., Ferre P., Fonfelle F.: Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu. Rev. Nutr., 1997, 17, 325.
12. Gylling H., Kontula K., Koivisto U.M., et al.: Polimorphism of the genes encoding apolipoproteins AI, B, CIII, and E and LDL receptor, and cholesterol and LDL metabolism during increased cholesterol intake. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 38.
13. Hegele R.A., Wolever T.M., Story A., et al.: Intestinal fatty acid binding protein variation associated with variation in the response of plasma lipoproteins to dietary fibre. Eur. J. Clin. Invest., 1997, 27, 857.
14. Humphries S.E., Nicaud V., Margalef J., et al.: Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglicerydes. EARS Study. Arterioscler. Thromb. Vase. Bio., 1998, 18, 526.
15. Jenkins D.Y., Hegele R.A., Jenkins A.L.: The apolipoprotein E gene and the serum low density lipoprotein cholesterol response to dietary fiber. Metabolism 1993, 42, 585.
16. Jump D.B., Clarce S.D.: Regulation of gene exspression by dietary fat. Annu. Rev. Nutr., 1999, 19, 63.
17. Kesaniemi Y.A., Ehnholm C., Mittinen T.A.: Intestinal cholesterol absorption efficiency in man is related to apolipoprotein E phenotype. J. Clin. Invest., 1987, 80, 578.
18. Kirke P.N., Mills J., Whitehead S., et al.: Methylenetetrahydrofolate reductase mutation and neural tube defects. Lancet 1996, 348, 1037.
19. Kłosiewicz L., Nowicka G., Grzybek A., et al.: Hypolipemic diet effect on lipoprotein profile in patients with hypercholesterolemia and mixed hyperlipidaemia in relation to apoE phenotype. Med. Sci. Monit., 1999, 5, 62.
20. Law M.: Salt, blood pressure and cardiovascular disease. J. Cardiol. Risk., 2000, 7, 5.
21. Loktinov A., Bingham S.A., Vorster H., et al.: Apolipoprotein E genotype modulates the effect of black tea drinking on blood lipids and blood coagulation factors: a pilot study. Br. J. Nutr., 1998, 79, 133.
22. Lopez-Miranda J., Jansen S., Ordovas J.M., et al.: Influence of the Sstl polymorphism at the apolipoprotein CIII gene locus on the plasma low-density lipoprotein cholesterol response to dietary monounsaturated fat. Am. J. Clin. Nutr., 1997, 66, 97.
23. Lopez-Miranda J., Ordovas J.M., Ostos M.A., et al.: Effect of the human apolipoprotein AI promoter G/A mutation on postprandial lipoprotein metabolism. Circulation 92, Suppl I, 156 (abstract).
24. Mager A., Lalezari S., Shohat T., et al.: Methylenetetrahydrofolate reductase genotypes and early onset coronary artery disease. Circulation 1999, 100, 2406.
25. Malloy A.M., Daly S., Mills J., et al.: Thermolabile variant of 5,10-methylene-tetrahydrofolate reductase associated with low red cell folates: implications for folate intake recommendations. Lancet 1997, 349, 1591.
26. Marshall J.A., Kamboh M.I., Bessesen D.H., et al.: Association between dietary factors and serum lipids by apolipoprotein E polimorphism. Am. J. Clin. Nutr., 1996, 63, 87.
27. Mata P., Ordovas J.M., Lopez-Miranda J., et al.: Apo AIV phenotype effects diet-induced plasma LDL cholesterol lowering. Arterioscler. Thromb. 1994, 14, 884.
28. McCombs R.J., Marcadis D.E., Ellis J., et al.: Attenuated hypercholesterolemic response to a high-cholesterol diet in subjects heterozygous for the apolipoprotein AIV-2 allele. N. Engl. J. Med., 1994, 331, 706.
29. Mettinen T.A., Gylling H., Vanhanent H., et al.: Cholesterol absorption, elimination and synthesis related to LDL kinetics during varying fat intake in men with different apolipoprotein phenotypes. Arterioscler. Thromb., 1992, 12, 1044.
30. Morton N.M., Emilsson V., Lin Y., et al.: Leptin action i intestinal cells. J. Biol. Chem., 1998, 273, 26194.
31. Nowicka G.: Apolipoproteina E - białko odgrywające szczególną rolę w etiopatogenezie typu III HLP. Żyw. Człow Metab., 1988, 15, 56.
32. Nowicka G.: Lipoproteiny o wysokiej gęstości i ich rola w zwrotnym transporcie cholesterolu. Czyn. Ryz., 1993, 2, 18.
33. Nowicka G.: Współczesne spojrzenie na antyaterogenne działanie lipoprotein o wysokiej gęstości. Czyn. Ryz., 1998, 4, 12.
34. Ordovas J.M., Galluzzi J.R.: Genetic predictors of plasma lipid response to diet intervention. Curr. Atheroscler, Reports 1999, 1, 196.
35. Ordovas J., Miranda J., Mata P., et al.: Gen-diet interaction in determining lipid response to dietary intervention. Atherosclerosis 1995, 118, Suppl S11.
36. Pimstone S.N., Clee S.M., Gange S.E., et al.: A frequently occuring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postpradial chylomicron trigliceryde and retinyl palmitate response in normolipidemic carriers. J. Lipid. Res., 1996, 37, 1675.
37. Sainz J., Van Tornout J., Lord L., et al.: Vitamin D receptor gene polymorphism and bone density in prepubertal american girls of emexican descent. N. Engl. J. Mmed, 1997, 337, 77.
38. Salas J., Jansen S., Lopez-Miranda J., et al.: The Sstl polymorphism of the apolipoprotein CIII gene determines the insulin response to an oral glucose tolerance test after consumptoon of a diet rich in saturated fats. Am. J. Clin. Nutr., 1998, 68, 396.
39. Schroeder F., Jolly C.A., Cho T., et al.: Fatty acid binding isoform: structure and function. Chem. Phys. Lipids 1998, 92, 1.
40. Sigurdsson G., Gudnason V., Humphries S.E.: Interaction between a polymorphism of the apoAl promoter region and smoking determines plasma levels of HDL and apo Al. Arterioscler. Thromb., 1992, 12, 1017.
41. Steinmetz A., Barbaras R., FGGhalim N., et al.: Human apolipoprotein AIV binds to apolipoprotein AI/AII receptor sites and promotes cholesterol efflux from adipose cells. J. Biol. Chem., 1990, 265, 7859.
42. Tikkanen M.J., Xu C.F., Hamalainen T., et al.: Xabl polimoprphism of the apolipoprotein B gene influences plasma lipid response to diet intervention. Clin. Genet., 1990, 37, 327.
43. Tiret L., de Knijff P., Menzel H.J., et al.: Apo E polymorphism and predisposition to coronary heart disease in youths of different european populations. The EARS Study. Arterioscler.Thromb. Vase. Biol., 1994, 14, 1617.
44. Tso P., Min Lin, Kologeris T.J.: The role of apolipoprotein AIV in food intake regulation. J. Nutr., 1999, 129, 1503.
45. Van Nieuwenhoven F.A., Van der Vusse G.J., Glatz J.F.: Membrane associated and cytoplasmic fatty acid binding proteins. Lipids 1996, 31, Suppl, S223.
46. Wang C.S., McConathy W.Y., Kloer H.U., et al.: Modulation of lipoprotein lipase activity by lipoproteins. Effect of apolipoprotein CIII. J. Clin. Invest., 1985, 75, 384.
47. Waterworth D.M., Ribalto J., Nicaud V., et al.: Apo CIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 1999, 99, 1872.
48. Weisgraber K.H., Mahley R.W., Kowal R.C., et al.: Apolipoprotein C modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins and inhibits binding of beta-VLDL to low density lipoprotein receptor - related protein. J. Biol. Chem., 1990, 265, 22453.
49. Wilson P., Schaefer E., Iarson M., et al.: Apolipoprotein E alleles and risk of coronary artery disease. A metaanalysis. Arterioscler. Thromb. Vase. Biol., 1996, 16, 1250.
50. Wittrup H.H., Tybjaerg-Hansen A., Steffensen R.: Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen City Heart Study. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 1535.
51. Wittrup H.H., Tybjaerg-Hansen A., Nordesgard B.G.: Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A metaanalysis. Circulation 1999, 99, 2901.
52. Yamada K., Yuan X., Ishiyema S.: Association between Ala54Thr substitution of the fatty acid binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men. Diabetologia 1997, 40, 706.